1. Home
  2. SLRX vs ARTL Comparison

SLRX vs ARTL Comparison

Compare SLRX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.78

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.95

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRX
ARTL
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLRX
ARTL
Price
$0.78
$1.95
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
664.7K
1.2M
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$1.52
52 Week High
$108.00
$28.60

Technical Indicators

Market Signals
Indicator
SLRX
ARTL
Relative Strength Index (RSI) 26.09 42.42
Support Level $0.81 $1.69
Resistance Level $0.89 $1.94
Average True Range (ATR) 0.07 0.20
MACD 0.10 0.11
Stochastic Oscillator 0.00 76.76

Price Performance

Historical Comparison
SLRX
ARTL

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: